Follow-up Care of Breast Cancer Patients

Dr. Simon D. Baxter, MD, FRCPC

Medical Oncologist

BC Cancer – Kelowna

Clinical Instructor, Dept of Medicine

University of British Columbia

19 April 2018





Disclosures

- **Employment:** none
- **Leadership:** none
- Consulting: Genomic Health, Celgene, Amgen
- Speaking: Roche, Pfizer, Genomic Health, Bayer, Astra Zeneca
- Expert testimony: none
- Ownership: none
- Research funding: none
- Intellectual property: none

Breast cancer scenario – Mrs. L

- Mrs. L is a 66 yo, post-menopausal woman
- Normal screening mammograms 1995-2013
- Left breast abnormality detected on mammogram
- Core Bx = invasive lobular carcinoma
 - ER+ PR+ Her2-negative
- Left partial mastectomy + SLNBx
 - pT3 (5.1 cm) pN1 (2/2 sentinel nodes), margins +
- Completion bilateral mastectomy and left ALND
 - Margins negative, 2 of 9 nodes involved
- Staging investigations for metastatic disease, including CT scan and bone scan, were negative

Breast cancer scenario – Mrs. L

- Oncologist indicates a high risk of recurrence, upwards of 50% in the next 10 years
 - Recommends adjuvant chemo, and radiotherapy
- Treatment completed 10 months after her first biopsy
- Adjuvant hormonal therapy initiated
 - Bone density indicates T = -2.3 in femoral neck
 - Plan for 2-3 years Tamoxifen followed by 2-3 years
 Aromatase inhibitor
 - Accompanied by bisphosphonate

Breast cancer scenario – Mrs. L

- After all of that...
 - You receive a discharge letter from BC Cancer requesting you to kindly follow-up with Mrs. L

Overview

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues

Breast cancer overview

Breast cancer is extremely common

Most common cancer type in women

1 in 8 women is expected to develop breast cancer

Estimated 3800 new breast cancer cases in 2017

- Breast cancer survival rates are good
 - 5-year relative survival rate of 88% if diagnosed between 2005-2009
- The number of breast cancer survivors continues to rise dramatically
 - In 2004 there were ~18,000 survivors
 - In 2014 there were ~24,000 survivors
- The care of these patients must be shared between family physicians and specialists

Breast cancer overview

Most common cancers diagnosed among BC cancer survivors

Cancer Group	Females	Males	Total
Prostate	0	25,300	25,300
Breast	24,444	166	24,610
Colorectal	7,061	8,654	15,715
Melanoma (Skin)	3,447	3,687	7,134
Bladder	1,629	5,166	6,795
Lung	3,339	2,756	6,095
Non-Hodgkin Lymphoma	2,705	3,198	5,903
Uterus	5,095	0	5,095
Leukemia	1,488	2,336	3,824
Kidney	1,099	1,992	3,091
Thyroid	2,293	769	3,062
Oral	977	2,033	3,010
All Cancers	62,567	65,059	127,626

Overview

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues

Survivorship

- What is "survivorship"?
 - Is it Life after cancer?
 - Is it Living with cancer?
 - Does it imply being cancer free?

- "Living with, through, and beyond cancer"
 - Begins at diagnosis
 - Includes people who continue to receive treatment to reduce recurrence or manage chronic disease


Survivorship

- Survivorship issues for breast cancer patients are broad
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Managing related concerns
 - Neuropathy, lymphedema, sexuality, fertility, menopause
 - Other health issues
 - Bone health, heart disease, diet, exercise, smoking, alcohol, mental health, relationships


Overview

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues

 Early stage ER+ breast cancer has significant long-term risk of relapse after 5y adjuvant tx



 Timing of recurrence of early stage breast cancer varies by receptor status



- Physician visits every 6 months x 5 years, then yearly
- History
 - Breast, axilla or skin changes
 - New symptoms, esp. unexplained and persistent
 - Medication adherence
 - New medications
 - Updated family history
- Physical exam
 - Breasts (chest wall), axilla, lymph nodes
 - Heart, lungs, spine, abdomen

Imaging

Diagnostic mammography qYearly

- MRI
 - If very high risk (BRCA1/2)
 - Dense breast tissue
 - Lobular cancer
 - Occult primary on mammogram

- Early detection of recurrence can be curative
 - In-breast recurrence
 - Chest wall, or lymph node recurrence
 - Limited regional recurrence
 - Oligometastatic disease


Overview

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues


Recall Mrs. L...

- Adjuvant hormonal therapy initiated
 - Bone density indicates T = -2.3 in femoral neck
 - Plan for 2-3 years Tamoxifen followed by 2-3 years
 Aromatase inhibitor
 - Accompanied by bisphosphonate

 Adjuvant tamoxifen for ~5 years reduces risk of ER+ breast cancer recurrence



 Adjuvant aromatase inhibitor for ~5 years reduces recurrence rates further compared to tamoxifen for post-menopausal women





EBCTCG. JCO. 2010. 28(3):509-518

- What are options for hormonal therapy?
 - Tamoxifen (±OFS) x 5y
 - Tamoxifen x 10 y
 - Aromatase inhibitor (±OFS) x 5 y
 - Aromatase inhibitor x 10 y
 - Tamoxifen x 2-5 y \rightarrow Aromatase inhibitor x 2-5 y

Compliance / adherence is a challenge!

- Adherence
 - At least 14% of patients
 will stop hormonal
 therapy due to side
 effects
 - Low adherence leads to worse disease free survival





Important to ask about adherence

Remind patients of the benefits

Explore reasons for low adherence

Manage side effects when possible

- Hot flushes
 - Avoidance of triggers, Acupuncture, SSRIs, natural health products
- Arthralgias / myalgias
 - Exercise, Analgesics, Massage, Acupuncture
- Vaginal irritation
 - Water-based lubricants, lowest-dose topical estrogens

Overview

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues

Other health issues

- Bone health
 - Aromatase inhibitor use is a risk factor for osteoporosis

	5 yrs Aromatase Inhibitor	10 yrs Aromatase Inhibitor	
New-onset osteoporosis	6%	11%	
Bone fracture	9%	14%	

Bone health

 Bone mineral density should be tested prior to starting aromatase inhibitor

 Severe osteopenia, or osteoporosis is a relative contraindication to aromatase inhibitor

- Bone health
 - Ensure adequate calcium and vitamin D intake,
 preferably from dietary sources
 - Avoid smoking
 - Avoid glucocorticoids
 - Encourage exercise
 - Consider bisphosphonates
 - May reduce breast cancer recurrence and mortality

Summary

- Mrs. L is doing well nearly 3 yrs after diagnosis
- She had breast reconstruction surgery
- She remains on Tamoxifen, and is managing side effects reasonably well
- She enjoyed vacationing in the tropics over the winter

Summary

- Survivorship issues for breast cancer patients
 - Screening for recurrence
 - Preventing recurrence
 - Managing medications
 - Other health issues

Selected Resources

- BC Cancer Cancer Management Guidelines Breast Cancer Survivorship. http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/breast/breast#7-Survivorship-Care
- BC Cancer Your Survivorship Care Plan <u>http://www.bccancer.bc.ca/survivorship-site/Documents/Generic%20CP%20Electronic%20-</u> <u>%20revised%20June%202013.pdf</u>
- ASCO ANSWERS Cancer Survivorship <u>https://www.cancer.net/sites/cancer.net/files/cancer_survivorship.pdf</u>

Thank you!

Questions / Comments ?